Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Potential Benefit of Renin-angiotensin System Inhibitors (RASi, ACEi/ARB) in High-risk Patients With COVID-19. The COVID-RASi Trial

NCT04591210 is registered in ClinicalTrials.gov with Ottawa Heart Institute Research Corporation as lead sponsor.

NCT NCT04591210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04591210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Potential Benefit of Renin-angiotensin System Inhibitors (RASi, ACEi/ARB) in High-risk Patients With COVID-19. The COVID-RASi Trial
Lead sponsor
Ottawa Heart Institute Research Corporation
Phase
Phase 3
Overall status
Completed
Start date
January 27, 2021
Completion date
December 30, 2024
Enrollment
372 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, covid-19